Companies combining valuable devices with known drugs may be able to land a high-value exit before ever hitting the market, MIT researcher Michael Cima told a group of medical device industry leaders today.

Speaking at the Cooley Medical Device Growth conference in Boston, Cima urged med-tech companies and investors to consider drug-device combinations, acknowledging a higher up-front risk with the potential for an earlier and larger reward.